On March 31, 2026, China’s National Medical Products Administration (NMPA) issued the Announcement on Matters Related to Cosmetic Registration and Filing (Draft for Comments) and is now soliciting public comments.

Globally, the regulatory landscape for exosome cosmetics exhibits significant variability. This article systematically reviews the management measures, regulations, and ethical standards concerning exosome cosmetics in various countries/regions, including the United States, the European Union, Japan, South Korea, Taiwan, and mainland China. It explores the context of compliance and prohibitions, as well as their impact on industry development, providing comprehensive global regulatory compliance guidance for cosmetic companies.

On March 11, 2026, the U.S. Food and Drug Administration (FDA) launched a new unified platform for analyzing adverse event reports, known as the FDA Adverse Event Monitoring System (AEMS). This initiative marks a significant milestone in the agency’s mission to modernize and enhance transparency regarding the safety of regulated products.On March 11, 2026, the U.S. Food and Drug Administration (FDA) launched a new unified platform for analyzing adverse event reports, known as the FDA Adverse Event Monitoring System (AEMS). This initiative marks a significant milestone in the agency’s mission to modernize and enhance transparency regarding the safety of regulated products.

The following FAQs are all related to ordinary cosmetics filing, CIRS Group has compiled the information and translated it into English for your reference.

Based on data retrieved from China’s National Medical Products Administration (NMPA), nine new cosmetic ingredients have been filed between March 1 and March 12, 2026. Detailed information is provided in the table below. At present, the associated technical specifications have not been made public, and the ingredient has not yet entered the post-filing monitoring period. As of now in 2026, a total of 45 new cosmetic ingredients have been filed.

In February, the U.S. Food and Drug Administration (FDA) announced updates to the Cosmetics Direct electronic submission portal, along with the user guide and other materials, to assist in the biennial registration renewal of cosmetic product facilities as required under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).

This article compiles and summarizes the latest developments in cosmetics regulations as of February 2026, including domestic China industry news, newly issued regulations, updates to relevant standards and policies, and regulatory requirements, as well as global regulatory trends in the cosmetics sector. It aims to assist enterprises in ensuring compliance and keeping up with global cosmetics regulatory trends.

Recently, the Beijing Cosmetics Review and Inspection Center has published a series of Q&A regarding ordinary cosmetics filing. The following content is primarily excerpted from the 53rd issue, compiled by CIRS Group for reference.

On February 12, 2026, Indonesia submitted notification G/TBT/N/IDN/184 to the World Trade Organization (WTO), detailing the draft regulation regarding the Form and Procedures for the Labelling of Non-Halal Information. This initiative introduces uniform standards for the labeling of “Non-Halal”, ensuring consistency across products marketed within Indonesia. The deadline for comments is set for March 14, 2026.

On February 23, 2026, the Korea Cosmetics Association (KCIA) announced plans to amend the Cosmetics Act. Proposed by Assemblyman Kim Ki-woong, this amendment aims to regulate the accuracy of information in cosmetics labels and advertisements, ensuring that claims about the environmental characteristics or efficacy of cosmetics and their containers and packaging (such as biodegradability) comply with standards set by relevant international organizations or the Prime Minister's orders. The KCA is currently seeking public feedback, with the deadline for submissions set for February 27, 2026.